Nonoperative Management of Primary Colorectal Cancer in Patients With Stage IV Disease
- 303 Downloads
Background: Traditional teaching maintains that patients with primary colorectal adenocarcinoma require timely resection to prevent bleeding, perforation, or obstruction. The true benefits of primary tumor resection remain undocumented for patients presenting with metastatic disease, however. We postulated that resection of primary colorectal tumors could be avoided safely in a select population of asymptomatic colorectal cancer patients presenting with incurable stage IV disease.
Methods: A retrospective review of the Vanderbilt University Hospital tumor registry was performed for the years 1985 to 1997. During this period, 955 patients presented for management of primary colorectal cancer. From this group, all patients with stage IV disease at the time of diagnosis were identified. Patients who initially underwent resection of their primary lesion were included in the resection group; those who underwent initial nonoperative primary tumor management were included in the nonresection group. Data were obtained regarding age, extent of disease, nonsurgical therapy, tumor-specific complications, and palliative surgical procedures. Surgery-free survival and overall survival were analyzed using the Kaplan-Meier method. For patients with liver metastases, hepatic tumor burden was defined as either H1 (<25% parenchymal replacement), H2 (25% to 50%), or H3 (>50%) disease.
Results: Sixty-six patients were included in the resection group, and 23 patients with intact asymptomatic primary colorectal lesions were included in the nonresection group. Among patients with hepatic metastases, most of the patients in both groups had H1 disease. Ten patients in the resection group and 3 patients in the nonresection group presented with exclusively extrahepatic metastases. In the nonresection group, primary therapy included chemotherapy in 13 patients, external beam radiation therapy in 1 patient, and combination chemoradiation in 9 patients. The median survival in the nonresection group was 16.6 months. The 2-year actuarial survival was 18%, and the surgery-free survival was 91.3%. Only 2 of 23 patients (8.7%) managed without resection eventually developed obstruction at the primary tumor site requiring emergent diversion. There were no episodes of tumor-related hemorrhage or perforation. For the resection group, the operative morbidity was 30.3%, and the perioperative mortality rate was 4.6%. The median survival in the resection group was 14.5 months (P = 0.59, log-rank test vs. nonresection group).
Conclusions: Selected patients with asymptomatic primary colorectal tumors who present with incurable metastatic disease may safely avoid resection of their primary lesions, with an anticipated low rate of hemorrhage, perforation, or obstruction before death from systemic disease. No survival advantage is gained by resection of an asymptomatic primary lesion in the setting of incurable stage IV colorectal cancer.
Key WordsColorectal cancer Metastatic Nonoperative Survival
Unable to display preview. Download preview PDF.
- 1.American Cancer Society. 1998 Cancer Facts and Figures. Atlanta, American Cancer SocietyGoogle Scholar
- 6.Piedbois P, Buyse M, Blijham G, et al. 1994 Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 12:960–969.Google Scholar
- 7.Nordic Gastrointestinal Tumor Adjuvant Therapy Group. 1989 Sequential methotrexate/5-fluorouracil/leucovorin (MFL) is superior to 5-fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial. J Clin Oncol 7:1437–1446.Google Scholar
- 8.Nordic Gastrointestinal Tumor Adjuvant Therapy Group. 1992 Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 10:904–911.Google Scholar
- 11.Habeshaw T, Adam JS. 1982 Weekly large fraction radiotherapy and 5-fluorouracil as a palliative treatment for large bowel carcinoma: a pilot study. J Radiat Oncol Biol Phys 8:1127–1130.Google Scholar
- 12.O’Connell MJ, Childs DS, Moertel CG, et al. 1982 A prospective controlled evaluation of combined pelvic radiotherapy and methanol extraction residue of BCG (MER) for locally unresectable or recurrent rectal carcinoma. J Radiat Oncol Biol Phys 8:1115–1119.Google Scholar
- 14.Rominger CJ, Gelber RD. 1985 Radiation therapy alone or in combination with chemotherapy in the treatment of residual or inoperable carcinoma of the rectum and rectosigmoid or pelvic recurrence following colorectal surgery. Am J Clin Oncol (CCT) 8:118–127.Google Scholar
- 16.Ota DM, Skibber J, Rich TAM.D. 1992 Anderson Cancer Center experience with local excision and multimodality therapy for rectal cancer. Surg Oncol Clin North Am 1:147–152.Google Scholar
- 20.Canon CL, Baron TH, Morgan DE, et al. 1997 Treatment of colonic obstruction with expandable metal stents: radiologic features. Am J Radiol 168:199–205.Google Scholar